Acquisition
Aug 2025AbbVie announced a definitive agreement to acquire bretisilocin for up to $1.2 billion, including upfront payment and milestones, and Gilgamesh planned to spin out the remaining company and programs.
SourceGilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Company research
Public company, workplace, funding, and market signals
Overview
Gilgamesh Pharmaceuticals is a New York-based clinical-stage neuroscience biotech founded in 2019 that develops novel chemical entities for psychiatric disease, with a focus on rapid-acting, durable therapies. Its current lead program is blixeprodil (GM-1020), an oral NMDA receptor antagonist for major depressive disorder; its earlier lead, bretisilocin, was acquired by AbbVie in 2025.
Primary product
Blixeprodil (GM-1020)
Founded
2019
Headquarters
New York, New York, United States
Team size
20-30
Work style
Flexible
Industry
Pharmaceutical Manufacturing
Sub-industry
Clinical-stage neuroscience biotech
Offices
Open Positions
0 jobs at Gilgamesh Pharmaceuticals
No open positions
Check back later for new openings